Cheshire, UK -- (MARKET WIRE) -- December 28, 2006 --
Protherics PLC
Total Voting Rights and Share Capital
London, UK; Brentwood, TN; 28 December 2006 - In conformity with the
Transparency Directive's transitional provision 6, Protherics PLC
("Protherics"), the international biopharmaceutical company
focused on critical care and cancer, is required to notify the
market of the following:
Protherics' issued share capital consists of 261,489,793 ordinary shares with a
nominal value of 2 pence each, with voting rights. Protherics does not hold any
ordinary shares in Treasury.
Therefore, the total number of voting rights in Protherics is 261,489,793.
The above figure of 261,489,793 shares may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in,
Protherics under the Financial Service Authority's Disclosure and Transparency
Rules.
Ends
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, David Yates +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END